RT Journal Article
T1 Flow cytometry for fast screening and automated risk assessment in systemic light-chain amyloidosis.
A1 Puig, Noemi
A1 Paiva, Bruno
A1 Lasa, Marta
A1 Burgos, Leire
A1 Perez, Jose J
A1 Merino, Juana
A1 Moreno, Cristina
A1 Vidriales, Maria-Belen
A1 Toboso, Dolores Gómez
A1 Cedena, Maria-Teresa
A1 Ocio, Enrique M
A1 Lecumberri, Ramon
A1 García de Coca, Alfonso
A1 Labrador, Jorge
A1 Gonzalez, Maria-Esther
A1 Palomera, Luis
A1 Gironella, Mercedes
A1 Cabañas, Valentin
A1 Casanova, Maria
A1 Oriol, Albert
A1 Krsnik, Isabel
A1 Pérez-Montaña, Albert
A1 de la Rubia, Javier
A1 de la Puerta, Jose-Enrique
A1 de Arriba, Felipe
A1 Prosper, Felipe
A1 Martinez-Lopez, Joaquin
A1 Lecrevisse, Quentin
A1 Verde, Javier
A1 Mateos, Maria-Victoria
A1 Lahuerta, Juan-Jose
A1 Orfao, Alberto
A1 San Miguel, Jesús F
AB Early diagnosis and risk stratification are key to improve outcomes in light-chain (AL) amyloidosis. Here we used multidimensional-flow-cytometry (MFC) to characterize bone marrow (BM) plasma cells (PCs) from a series of 166 patients including newly-diagnosed AL amyloidosis (N = 94), MGUS (N = 20) and multiple myeloma (MM, N = 52) vs. healthy adults (N = 30). MFC detected clonality in virtually all AL amyloidosis (99%) patients. Furthermore, we developed an automated risk-stratification system based on BMPCs features, with independent prognostic impact on progression-free and overall survival of AL amyloidosis patients (hazard ratio: ≥ 2.9;P ≤ .03). Simultaneous assessment of the clonal PCs immunophenotypic protein expression profile and the BM cellular composition, mapped AL amyloidosis in the crossroad between MGUS and MM; however, lack of homogenously-positive CD56 expression, reduction of B-cell precursors and a predominantly-clonal PC compartment in the absence of an MM-like tumor PC expansion, emerged as hallmarks of AL amyloidosis (ROC-AUC = 0.74;P 
YR 2018
FD 2018-12-12
LK https://hdl.handle.net/10668/26671
UL https://hdl.handle.net/10668/26671
LA en
DS RISalud
RD Apr 10, 2025